Aside from Seagen, small takeouts dominate the first quarter.
US Pdufa decisions loom for Apellis and Travere, while Menarini and Lilly got their approval firsts already.
December’s $28bn takeout of Horizon bumps 2022’s M&A numbers to respectable levels.
2023 begins with FDA decisions for Eisai’s Alzheimer’s project and Pfizer’s zavegepant, with an adcom for Cidara’s rezafungin.
The group looks like the gene therapy contender to beat, but that is not saying much.
But questions about gene therapy safety could benefit the enzyme-replacement therapy incumbents.